Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials

This publication has 74 references indexed in Scilit:

• Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
  Published by Elsevier ,2004
• Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
  New England Journal of Medicine, 1999
• Phase I dose escalation, pharmacokinetic (pk) study of a novel vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK)
  European Journal Of Cancer, 1999
• Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470
  New England Journal of Medicine, 1998
• BCL-2 FAMILY: Regulators of Cell Death
  Annual Review of Immunology, 1998
• 1180: First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial
  European Journal Of Cancer, 1997
• Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
  Nature Medicine, 1995
• Apoptosis of vascular endothelial cells by fibroblast growth factor deprivation
  Biochemical and Biophysical Research Communications, 1990
• Morphometric study of myocardial changes during doxorubicin-induced cardiomyopathy in mice
  European Journal of Cancer and Clinical Oncology, 1988
• Tumor Angiogenesis: Therapeutic Implications
  New England Journal of Medicine, 1971